Altis Biosystems, Inc.
Durham, NC · Founded 2018 · CIK 0001799892 · Medtech
RepliGut® StemScreen, a high-throughput plate-based assay platform for screening pharmaceutical effects on human GI stem cells
altisbiosystems.com →- Grants
- $16M
- 19 awards
- Sector median: 1
- Raised
- $4.4M
- 3 Form D · Apr 2025
- 18 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 2
- 0 granted · 2 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201820192020202120222023202420252026
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Co-culture cassette for anaerobes and primary human intestinal epithelium | $224,898 | |
| Federal grant | Department of Health and Human Services · Phase I · Developing a platform and optimized cell system for enteroendocrine cell-based assays and compound screening | $223,049 | |
| Federal grant | Department of Health and Human Services · Phase II · Co-culture cassette for anaerobes and primary human intestinal epithelium | $1,493,382 | |
| Private capital raised | Form D · SEC | $938,592 | |
| Federal grant | Department of Health and Human Services · Phase I · Generating drug-screenable primary human intestinal epithelium by gene-editing and transgenesis | $245,920 | |
| Federal grant | Department of Health and Human Services · Phase II · Co-culture cassette for anaerobes and primary human intestinal epithelium | $745,742 | |
| Federal grant | Department of Health and Human Services · Phase II · Developing an optimized cell based platform for assays of the gastrointestinal enteroendocrine system | $1,412,331 | |
| Federal grant | Department of Health and Human Services · Phase II · Developing an optimized cell based platform for assays of the gastrointestinal enteroendocrine system | $699,341 | |
| Federal grant | Department of Health and Human Services · Phase I · A 2D Intestinal Crypt Platform for Compound Screens | $256,543 | |
| Federal grant | Department of Health and Human Services · Phase II · InflammaGut: a drug-screenable co-culture system using gut-associated lymphocytes and autologous primary human gut epithelium that reports inflammation | $1,980,716 | |
| Federal grant | Department of Health and Human Services · Phase I · A Mucus-producing Intestinal Epithelium Model for In Vitro Drug Absorption Testing | $293,991 | |
| Federal grant | Department of Health and Human Services · Phase I · Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk | $256,574 | |
| Private capital raised | Form D · SEC | $1,363,658 | |
| Federal grant | Department of Health and Human Services · Phase II · A 2D Intestinal Crypt Platform for Compound Screens | $1,888,698 | |
| Federal grant | Department of Health and Human Services · Phase II · InflammaGut: a drug-screenable co-culture system using gut-associated lymphocytes and autologous primary human gut epithelium that reports inflammation | $988,414 | |
| Federal grant | Department of Health and Human Services · Phase II · Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk | $913,659 | |
| Federal grant | Department of Health and Human Services · Phase II · A 2D Intestinal Crypt Platform for Compound Screens | $900,267 | |
| Federal grant | Department of Health and Human Services · Phase I · MetabolGut: a rapid assay platform to evaluate the impact drugs on lipid-handlingpathways and chylomicron-associated drug distribution using stem cell-drivenhuman absorptive enterocytes. | $343,297 | |
| Federal grant | Department of Health and Human Services · Phase II · Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk | $913,659 | |
| Private capital raised | Form D · SEC | $2,126,307 | |
| Federal grant | Department of Health and Human Services · Phase II · Mucus and ALI Models of the Human Intestine | $835,939 | |
| Federal grant | Department of Health and Human Services · Phase II · Mucus and ALI Models of the Human Intestine | $1,001,183 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1081 | CRESCEL LLC | — | $1.4M |
| 1082 | CALYX, INC. | — | — |
| 1083 | PROTEUS MOTION INC. | — | $16M |
| 1084 | Altis Biosystems, Inc. | — | $4.4M |
| 1085 | Orange Photonics, Inc. | — | $1.9M |
| 1086 | DropletPharm Inc. | — | — |
| 1087 | EMANATE WIRELESS, INC. | — | $1.0M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Michael BironDirector · Executive Officer
- Kevin CauseyDirector
- Michael DialDirector
- Samuel FranklinDirector
- Susan MahonyDirector
- Joseph McMahonDirector
- Christopher PerkinsDirector
- Benjamin ScruggsDirector · Executive Officer
- Christopher SimsDirector · Executive Officer
- Jimmy SmedleyExecutive Officer
Patents
- Cell Culture Systems Comprising Micropatterned Arrays And Methods Of Useapplication
- Cell Culture Systems Comprising Micropatterned Arrays And Methods Of Useapplication
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.